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Abstract
Semaphorins are a diverse family of immunoregulators recently recognized to play a major
role in various phases of immune responses. Their role in chronic viral hepatitis C (CHC)
and contribution to the progression of liver disease is unknown. The aim of this study was to
analyse the association of secreted semaphorins with the severity of liver disease in patients
with CHC. Serum concentrations of semaphorins were measured in 114 treatment-naive
CHC patients and 36 healthy controls. Serum concentrations of SEMA3A, SEMA3C,
SEMA5A, SEMA6B and SEMA6D were significantly increased in patients with CHC com-
pared to controls. While serum concentrations of SEMA3C and SEMA6D significantly
increased with fibrosis stage in both HCV-g1 and HCV-g3 infections, the concentration of
SEMA5A inversely correlated with fibrosis stage in both HCV genotypes. ROC analysis
showed that serum concentrations of SEMA3C (>4.0ng/mL, AUC 0.88) and SEMA6D (>4.5,
AUC 0.82) had higher AUC than widely used APRI (AUC 0.71) and FIB-4 (AUC 0.74)
scores. Serum concentrations of SEMA3C and SEMA6D significantly decreased after DAA
and PEG IFN-α/ribavirin therapy, while the serum concentration of SEMA5A significantly
increased after DAAs therapy. Immunohistochemistry confirmed the expression of
SEMA3C and SEMA5A in hepatocytes, endothelial cells and lymphocytes of cirrhotic livers
from CHC patients but not in controls. In conclusion, we provide the first evidence that
SEMA3C, SEMA5A and SEMA6D can be considered as markers of liver injury in CHC.
Introduction
Since its discovery 30 years ago, chronic hepatitis C (CHC) has evolved from an incurable dis-
ease to the prototype of chronic viral infection that can be easily and safely cured. Still, chronic
hepatitis C remains the leading cause of cirrhosis, hepatocellular carcinoma and liver trans-
plantation [1, 2]. Thus, the scientific focus in CHC research is moving rapidly from antiviral
treatment towards complications of chronic infection and its early identification. Now we are
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able to eliminate the virus, but significant gaps in the knowledge of biological and immunolog-
ical mechanisms of chronic infection, fibrogenesis and carcinogenesis remain.
System biology approaches and whole genome sequencing analyses have enabled us to
identify molecular signatures that might be associated with the lack of effective immune
responses, development of tolerance and low level inflammation associated with persistent
HCV infection [3–9]. In transcriptome studies of in vitro HCV infected liver non-parenchymal
cells, the semaphorin pathway emerged as a novel consistent finding associated with HCV
infection [5–7, 10].
Semaphorins are a large family of secreted and membrane-bound biological response mod-
ifiers present in many organ systems, including the nervous, epithelial, and immune system
that mediate the development, angiogenesis and oncogenic transformation [11–13]. A recent
research describes the role of selected semaphorins in cellular immunity and subsequent levels
of inflammatory response [12, 13]. While some suppress the immune cell activation, prolifera-
tion and reduce the production of pro-inflammatory cytokines, others stimulate the immune-
mediated responses [12, 13]. The importance of plexins and semaphorins has been further
emphasized in allergic and immune-mediated disorders, such as systemic lupus erythematosus
(SLE), asthma, psoriasis, and multiple sclerosis [14]. So far, semaphorins have not been studied
in HCV infected patients.
Based on the potential correlation between semaphorins‘expression and disease progres-
sion, we hypothesized that semaphorins are associated with liver fibrosis resulting from
chronic viral hepatitis and therefore may be a novel biomarker of liver cirrhosis. In the present
study we investigated the expression profiles of selected semaphorins in the sera and liver sam-
ples from HCV infected patients, their correlations with clinicopathological data and treat-
ment outcomes. The potential usefulness as biomarkers for early diagnosis of liver cirrhosis
was also assessed.
Materials and methods
Patients and samples
The prospective study included 114 treatment-naive adult patients with chronic hepatitis C
receiving clinical care at the Croatian Reference Center for Viral Hepatitis, Zagreb, Croatia
between January 2016 and September 2018. All patients tested negative for HIV and HBV
infection. Additionally, paired samples before and 12 weeks after antiviral therapy were ana-
lyzed in 23 patients (14 treated with direct acting antivirals without interferon, and 9 patients
treated with pegylated interferon alpha) that achieved sustained virological response (SVR,
defined as undetectable HCV RNA at 12 weeks after the end of antiviral therapy). 36 voluntary
blood donors without relevant medical history and without obesity, the use of medication and/
or alcohol abuse were included as healthy controls (HC).
The patients were enrolled consecutively upon signing the informed consent. Ethical
approval was obtained from the Ethics Committee at the University Hospital for Infectious
Diseases Zagreb, Croatia, in accordance with the declaration of Helsinki.
Whole blood samples were collected by venipuncture into sterile tubes without anticoagu-
lant and the blood was allowed to clot for 20 minutes at room temperature. Serum was sepa-
rated by centrifugation at 2000xg for 10 min. The samples were divided into aliquots to avoid
repeated freeze and thaw cycles and stored at -80˚C until testing.
Additionally, immunohistochemistry was performed on specimens obtained from 6
patients at the Liver Transplant Center (University Hospital Merkur, Zagreb, Croatia). Three
specimens were obtained from healthy liver donors immediately after the explantation and
three from the explanted cirrhotic CHC livers.
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Methods
The routine workup included complete blood count, liver function tests, HCV and HBV
markers and HIV Ag/Ab, which were performed using commercially available assays. HCV
RNA was quantified by using the standardized real-time PCR assay Abbott Real Time HCV
test (Abbott Molecular, Illinois, USA) with a lower limit of detection of 12 IU/mL.
HCV genotypes were determined by using the Versant HCV genotype 2.0 Assay (Siemens
Healthcare Diagnostics, Erlangen, Germany). The stage of liver fibrosis was assessed by tran-
sient elastography (Fibroscan, Echosens, Paris, France) [15]. APRI and FIB-4 score were calcu-
lated for all patients and were used as a surrogate marker of disease severity [16, 17]. The
quantification of semaphorins was performed by using the standardized ELISA assays
(Human Semaphorin -3A, -4D, -3C, -5A, -6B and -6D ELISA Kit, MyBioSource, San Diego,
CA, USA), as recommended by the manufacturer. Quantification ranges of semaphorin ELI-
SAs were as follows: SEMA-3A (31,25–2000 pg/ml), SEMA-4D (0,625–20 ng/ml), SEMA-3C
0–10 ng/ml, SEMA-5A (0,78–50 ng/ml), SEMA-6B (0,625–20 ng/ml) and SEMA-6D (0,625–
20 ng/ml).“
Immunohistochemical staining: unstained slides (4 μm thick) were generated from the
whole tissue blocks (2 blocks per case) for immunohistochemical staining using antibodies
SEMA3C and SEMA5A. Immunohistochemical staining was performed in the automated
immunostainer (Dako Autostainer, LINK 48, Denmark) using Envision (DAKO Denmark)
for SEMA3C and ImmPRESS (Vector laboratories, USA) polymer detection systems for
SEMA5A according to the manufacturer’s instructions. Rabbit polyclonal anti-semaphorin 3C
antibody (Abcam, Cambridge, UK) was used at 1:50 dilution. Goat polyclonal anti-sema-
phorin 5A antibody (Abcam, Cambridge, UK) was used at 1:80 dilution. Human pancreas tis-
sue was used as a positive control for SEMA3C expression and human colon tissue as a
positive control for SEMA5A expression (both cytoplasmic staining). For the negative control,
adjacent tissue sections were stained without the primary antibody.
Statistical analysis
The demographic, clinical characteristics and laboratory data were evaluated and presented
descriptively. Categorical data were expressed in frequencies and relevant percentage. The sig-
nificance of the observed differences in frequencies between relevant subgroups was tested
with the chi-square test or the Fisher’s exact test when appropriate. For continuous variables,
we calculated mean values with standard deviations or median values with 25th and 75th per-
centile depending on distribution. Comparative statistics between two or more groups was
generated using the Mann–Whitney U or the Kruskal–Wallis test, as appropriate. Correlations
were analyzed using the Spearman’s rank correlation coefficient. The diagnostic performances
of the laboratory variables considered were compared using a receiver operating characteristic
(ROC) analysis. Sensitivity, specificity, positive and negative predictive values and likelihood
ratios (LRs) were calculated. All tests were two-tailed; a P< 0.05 was considered statistically
significant. Statistical analyses were performed using prism (ver 5.0) statistical software
(Graphpad Software, San Diego, CA) and MedCalc for Windows, ver 11.5.1.0 (MedCalc Soft-
ware, Mariakerke, Belgium).
Results
Patient characteristics
The characteristics of the patients are shown in Table 1. The majority of CHC patients were
infected with HCV genotype 1 (n = 70) and 44 patients were infected with genotype 3. CHC
Semaphorins in chronic hepatitis C
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patients were classified into four groups according to the transient elastography (F1 n = 22; F2
n = 22, F3 n = 28, F4 n = 42). The study also included 36 healthy controls (19 males, median
age of 51 years (IQR 39–59.7).
Elevated serum concentrations of semaphorins in patients with chronic
hepatitis C
We examined serum semaphorin concentrations in CHC group compared to healthy controls.
In comparison to healthy controls, serum levels of SEMA3A, SEMA3C, SEMA5A, SEMA6B
and SEMA6D were significantly higher in CHC patients, whereas only SEMA4D was not sig-
nificantly altered, as shown in Fig 1A. There was no difference in semaphorin expression in
healthy controls regarding sex and age.
Serum concentrations of SEMA3C, SEMA5A and SEMA6D correlate with
fibrosis stage
Next, we analyzed serum concentrations of semaphorins in different fibrosis stages and HCV
genotype infections (Fig 1B–1D). While serum concentrations of SEMA3C and SEMA6D sig-
nificantly increased with fibrosis stage in both HCV-g1 and HCV-g3 infection, serum concen-
tration of SEMA5A inversely correlated with fibrosis stage in both HCV genotypes. SEMA3A
and SEMA6B serum concentrations showed no correlation with fibrosis stage.
In CHC patients, both SEMA3C and SEMA6D showed correlation with the APRI (r = 0.38,
p<0.0001 and r = 0.36, p<0.0001, respectively) and FIB4 score (r = 0.39, p<0.0001 and
r = 0.37, p<0.0001). SEMA3C and SEMA6D showed positive correlation with AST (r = 0.25,
p = 0.0052 and r = 0.25, p = 0.0047, respectively), and negative correlation with platelet count
(r = -0.35, p<0.0001 and r = -0.33, p = 0.0003). SEMA5A inversely correlated with AST (r =
-0.23, p = 0.0125) and APRI (r = -0.36, p<0.0001) and FIB4 (r = -0.37, p<0.0001), and posi-
tively with platelet count (r = 0.35, p = 0.0001). Neither SEMA3C, SEMA6D nor SEMA5A cor-
related with age, viraemia and ALT.
Table 1. Baseline patient characteristics.
Fibrosis stage
1 2 3 4
Liver stiffness, kPa 5.5 (4.6–6.1) 7.9 (7.3–8.8) 10.2 (9.6–11) 19.2 (14.0–30.7)
Age, years 51.5 (43.7–65.5) 57 (51.75–65.25) 59.5 (41.5–66.7) 59 (48.7–63)
Male sex 10 (8.8%) 12 (10.5%) 12 (10.5%) 22 (19.3%)
HCV genotype 1 12 (10.5%) 14 (12.3%) 18 (15.8%) 26 (22.8%)
HCV genotype 3 10 (8.8%) 8 (7.0%) 10 (8.8%) 16 (14.0%)
HCV RNA, log 10 5.1 (4.9–5.4) 6.3 (5.2–6.7) 5.5 (4.5–6.1) 5.8 (5.2–6.1)
Aspartate transaminase, IU/L 45 (34.5–87.5) 61.5 (47–129) 79 (61.2–89) 82 (60.5–101.3)
Alanine transaminase, IU/L 67.5 (39.2–124.5) 77 (58.7–148) 97 (68–124.8) 92 (57–127.5)
Platelets, x109/L 230 (184–300) 202 (147–231) 131.5 (98.2–194.3) 122.5 (78–220.5)
Albumins, g/L 43 (38.3–45.3) 42 (37.5–44.7) 38.5 (35–42.0) 34.4 (26.7–40.8)
International normalized ratio 1 (0.99–1.12) 1.0 (0.9–1.1) 1.13 (1.0–1.3) 1.3 (1.1–1.8)
APRI score 0.53 (0.37–0.68) 0.93 (0.58–1.72) 1.69 (0.85–2.5) 1.57 (0.82–3.01)
FIB4 score 1.21 (0.89–2.14) 2.3 (1.5–4.2) 3.08 (2.08–5.19) 3.31 (2.05–6.35)
Presented are baseline patient clinical, laboratory and virological characteristics according to fibrosis stage as measured by transient elastography. Data are presented as
frequencies (%) or medians with interquartile ranges.
https://doi.org/10.1371/journal.pone.0209481.t001
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Serum SEMA3C and SEMA6D are superior to APRI and FIB-4 in
predicting the presence of cirrhosis and significant fibrosis
Based on the above-mentioned correlations, the diagnostic performances of the selected sema-
phorins were compared to routinely used APRI [16] and FIB-4 [17] scores using a receiver
operating characteristic (ROC) analysis.
Firstly, serum concentrations of SEMA3C and SEMA6D showed better sensitivity and spec-
ificity for detection of liver cirrhosis (>4.0, sensitivity 87.5%, specificity 78.8%, AUC 0.88 and
>4.5, sensitivity 72.9%, specificity 85.7%, AUC 0.82, respectively) as compared to widely used
APRI score (>1.4 sensitivity 68.7%, specificity 69.1%, AUC 0.71) or FIB-4 score (>3.25
Fig 1. Serum concentrations of semaphorins in patients with chronic hepatitis C (CHC) and healthy controls. (A) Patients with CHC have elevated
serum levels of semaphorins compared to healthy controls. Serum concentration of SEMA5A decreases with fibrosis progression (B), while serum
concentrations of SEMA3C (C) and SEMA6D (D) increase with fibrosis stage. Data are presented as median with interquartile range and analyzed by Mann-
Whitney U-test or Kruskal–Wallis test, as appropriate.
https://doi.org/10.1371/journal.pone.0209481.g001
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sensitivity 64.5%, specificity 70.4%, AUC 0.74), as shown in Fig 2A. Serum concentration of
SEMA5A <12ng/mL showed sensitivity of 85.0% and specificity of 63.3% (AUC 0.79) in the
detection of cirrhosis.
Secondly, we examined the diagnostic accuracy in detection of significant fibrosis (F2-F4).
Again, SEMA3C >3.5 (sensitivity 78.3%, specificity 89.4%, AUC 0.88), SEMA6D >3.0 (sensi-
tivity 77.0%, specificity 95.4%, AUC 0.90) and SEMA5A <15 (sensitivity 85.3%, specificity
72.3%, AUC 0.83) showed comparable discrimination of significant fibrosis as did APRI
(AUC 0.84) and FIB4 (AUC 0.85) scores, as shown in Fig 2B.
Serum levels of SEMA3C and SEMA6D decrease after DAA and PegIFNα
treatment
Next, we examined serum concentrations of semaphorins in 14 patients treated with DAAs
and 9 patients treated with PegIFNα before and 12 weeks after completion of treatment. At
baseline, liver fibrosis was classified as F1/2 in 39% and F3/4 in 61% of patients. Antiviral ther-
apy significantly improved fibrosis stage, as measured by fibroscan 12 weeks after treatment
completion, with 60% of cases classified as F1/2 after therapy (Fig 3A). After treatment all
patients had AST and ALT values within reference range.
Importantly, serum concentrations of SEMA3C and SEMA6D significantly decreased after
DAA (4.35, IQR 3.62–5.03 to 0.64, IQR 0.28–0.96, p<0.0001, and 4.13, IQR 1.2–5.85 to 1.69,
IQR 0.84–2.67, p = 0.0340, respectively) and PegIFNα therapy (3.49, IQR 2.00–5.03 to 1.46,
IQR 0.96–2.1, p = 0.0083 and 3.17, IQR 1.81–4.87 to 1.23, IQR 0.59–2.19, p = 0.0244, respec-
tively). The serum concentration of SEMA5A significantly increased after DAAs therapy
(11.05, IQR 8.67–15.75 to 15.75, IQR 13.65–22.88, p = 0.0241), but there were no significant
changes in patients treated with PegIFNα (Fig 3B–3D). There were no significant changes in
serum concentrations of SEMA6B.
Fig 2. The ROC curve of laboratory parameters for discrimination of liver cirrhosis (F4) (A) and significant liver fibrosis (F2-4) (B). Shown are
calculated cut-off values (Youden index), accuracy as measured by the area under the ROC curve (AUC) and probability as calculated p-values.
https://doi.org/10.1371/journal.pone.0209481.g002
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SEMA3C and SEMA5A expression in liver tissue samples
To gain further insight into tissue expression of SEMA3C and SEMA5A, we performed immuno-
histochemistry in cirrhotic CHC human livers in comparison to healthy donors. In healthy livers
SEMA3C and SEMA5A expression was not detected by immunohistochemistry, neither in hepa-
tocytes, nor in endothelial cells (Fig 4A and Fig 5A). By contrast, in CHC cirrhotic livers SEMA3C
and SEMA5A expression was detected in hepatocytes as well in endothelial cells and lymphocytes.
In HCV cirrhosis, SEMA3C showed moderate positivity in endothelial cells and lymphocytes (Fig
4C) and weak positivity in hepatocytes (Fig 4D). SEMA5A was expressed mostly in hepatocytes
(Fig 5B and 5C). In addition, SEMA3C and SEMA5A were expressed in HCV HCC samples.
Discussion
During chronic HCV infection, a sustained cytokine production drives persistent low-grade
inflammation in the absence of immunocompetent Th1 responses thus allowing the constant
Fig 3. Serum semaphorins levels and liver fibrosis in patients before and after antiviral therapy. Changes in the proportion of fibrosis (F1-4) (A), serum
SEMA3C (B), SEMA6D (C) and SEMA5A (D) in patients before and after antiviral therapy are shown. Paired patient concentrations are shown (n = 23). Data
were analyzed by Mann-Whitney U-test.
https://doi.org/10.1371/journal.pone.0209481.g003
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viral replication [18]. However, the understanding of these phenomena remains unclear. The
impairment of balance in the cytokine milieu modulates local T helper and Treg responses,
which are unable to eliminate the infection, but drive hepatic damage and fibrogenesis [19].
Indeed, many cytokines have shown to be good predictors of interferon treatment responses
[19, 20], however they failed to show the clinically relevant diagnostic accuracy in identifying
patients with severe fibrosis or therapeutic application.
There is growing evidence that the signaling pathways triggered by semaphorin interactions
with their receptors plexins and neuropilins influence the outcome of the immune responses;
while some suppress immune cell activation and proliferation, others stimulate immune-medi-
ated responses [21]. Here we provide the first evidence that semaphorins might play a role in
HCV infection as well.
Firstly, we demonstrated that circulating levels of SEMA3A, SEMA3C, SEMA5A, SEMA6B
and SEMA6D are detectable and elevated in the serum of patients with CHC. Class 3
Fig 4. Immunohistochemical staining of SEMA3C in healthy and cirrhotic HCV liver. While there is no expression of SEMA3C markers in healthy liver tissue (A,
magnification 40x), in cirrhotic HCV liver (B, magnification 10x), there is a moderate expression in endothelial cells and lymphocytes (C, magnification 40x) and weak
in hepatocytes (D, magnification 40x).
https://doi.org/10.1371/journal.pone.0209481.g004
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semaphorins, specifically SEMA3A, previously shown to inhibit the T-cell activation, act as a
positive regulator in the innate immune system by promoting proinflammatory cytokines pro-
duction [12, 13, 22]. The importance of SEMA3A in autoimmune disorders is highlighted by
the finding of reduced expression of SEMA3A in patients with rheumatoid arthritis and SLE
that correlates with T-cell mediated inflammation and disease severity [21]. Less is known
about the immunoregulatory role of SEMA3C, but it was shown that SEMA3C promotes the
migration of dendritic cells [12, 13]. SEMA4D, activator of T- and B- cells, was shown to
induce inflammation [12, 13]. SEMA5A promotes T-cell and NK cell proliferation and induces
the secretion of Th17 proinflammatory cytokines that are implicated in SLE and RA disease
activity [12, 14, 21]. SEMA6D is involved in the regulation of late phases of T-cell activation
and generation of T-cell memory [12, 21].
Secondly, we found that semaphorin expression correlates with fibrosis stage. The role of
semaphorins in fibrogenesis has not been studied, so the pathophysiological explanation of
our findings is to be determined. Our data show that SEMA3C and SEMA6D significantly
increase with fibrosis stage. Interestingly, pro-fibrogenic role of SEMA3C was shown in adi-
pose tissue where SEMA3C increased the production of extracellular matrix and growth fac-
tors that are associated with the pathogenesis of fibrosis [23]. Recently, class III semaphorins
were shown to induce the migration and invasive capacity of fibroblast-like synoviocytes in
the model of rheumatoid arthritis [24]. SEMA6D activates vascular endothelial growth factor-
receptor 2 implicated in liver fibrinogenesis [25]. We found that serum concentration of
SEMA5A inversely correlates with fibrosis. So far it was shown that SEMA5A regulates angio-
genesis by increasing endothelial cell proliferation, decreasing apoptosis and extracellular
matrix degradation through matrix metalloproteinase [26].
Next, we have shown that SEMA3C and SEMA6D have superior accuracy to APRI and
FIB-4 in predicting the presence of cirrhosis. Early and accurate assessment of the severity of
liver fibrosis is essential in the management and prognosis of patients with CHC and CHB.
Two most common non-invasive scores, APRI and FIB-4, that don’t require extra laboratory
testing, are limited in prediction of significant fibrosis with relatively low sensitivity (60% and
75%, respectively) and specificity (65% and 60%, respectively) [27].
Additionally, the concentrations of SEMA3C and SEMA6D decrease following treatment
with antiviral drugs (DAA) or a combination of immunomodulatory and antiviral drugs
(PegIFNα and ribavirin). These results show that successful treatment resulting in viral eradi-
cation reduces the intensity of semaphorin synthesis. Additionally, they suggest that HCV
infection itself, particularly in liver hepatocytes as shown by immunohistochemistry, might
represent a key stimulus for semaphorin synthesis in chronic infection.
Although our results are limited by the relatively small number of patients, we provide the
first evidence of the role of semaphorins in HCV infection. Due to ethical issues we assessed
the stage of liver fibrosis by non-invasive technics only, as recommended and described in cur-
rent international guidelines.
In conclusion, we demonstrated that circulating levels of SEMA3A, SEMA3C, SEMA5A,
SEMA6B and SEMA6D are detectable and elevated in the serum of patients with CHC. Based
on the correlation with the biochemical and fibroelastography degree of the liver damage,
SEMA3C, SEMA5A and SEMA6D can be considered markers of liver injury in CHC and are
superior to APRI and FIB-4 in predicting the presence of cirrhosis. The regulation of
Fig 5. Immunohistochemical staining of SEMA5A in healthy and cirrhotic HCV liver. While there is no expression
of SEMA5A markers in healthy liver tissue (A, magnification 40x), there is a strong expression in HCV cirrhotic livers
(B, magnification 10x), in endothelial cells and lymphocytes and in hepatocytes (C, magnification 40x).
https://doi.org/10.1371/journal.pone.0209481.g005
Semaphorins in chronic hepatitis C
PLOS ONE | https://doi.org/10.1371/journal.pone.0209481 December 28, 2018 10 / 12
semaphorins and their receptors could be a potential future therapeutic target to decrease liver
inflammation and fibrogenesis in chronic viral hepatitis.
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